New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside

Hot topic
Chairs: J. Hedner (Göteborg, Sweden), M. Bonsignore (Palermo, Italy)
Aims: to describe the control of hypoglossal motor activity across sleep-wake states and identification of pharmacological targets in a preclinical model; to describe the results of the first successful clinical trial of pharmacological therapy for obstructive sleep apnoea; to describe the role of leptin in upper airway motor control in obesity and the potential therapeutic implications; to describe clinical and translational data regarding the effect of carbon anhydrase inhibitors on sleep-disordered breathing.

Control of hypoglossal motor activity across sleep-wake states and identification of pharmacological targets R. Horner (Toronto (ON), Canada)
Ato-oxy as the first successful pharmacotherapy for obstructive sleep apnoea L. Taranto Montemurro (Chestnut Hill , United States of America)
Can leptin be used to treat obstructive sleep apnoea? V. Polotsky (Baltimore, United States of America)
Carbon anhydrase inhibitors for treatment of obstructive sleep apnoea J. Hedner (Göteborg, Sweden)